GlassScriptPhysician profile
Michael C Wismer
NPI 1265960702
$676.72
in general payments reported to CMS, 2019-2025
17 companies · $326 in 2025
The $326 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $351 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $83.70 | 2024-2025 | Enhertu, Injectafer |
| Incyte Corporation | $83.33 | 2024-2025 | Jakafi, Pemazyre, Monjuvi |
| Novartis Pharmaceuticals Corporation | $58.87 | 2025 | |
| Array Biopharma INC | $57.27 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Genentech USA, INC. | $53.74 | 2024 | Polivy, Lunsumio, Columvi |
| Merck Sharp & Dohme LLC | $49.11 | 2024-2025 | Keytruda |
| Genzyme Corporation | $48.25 | 2024-2025 | |
| Astellas Pharma US INC | $42.22 | 2024-2025 | Padcev |
| Regeneron Healthcare Solutions, INC. | $33.92 | 2025 | Libtayo |
| Abbvie INC. | $24.78 | 2025 | |
| Celgene Corporation | $24.10 | 2025 | Opdivo |
| Lilly USA, LLC | $23.58 | 2024 | Jaypirca |
| Pharmaessentia USA Corporation | $21.65 | 2024 | Besremi |
| Pfizer INC. | $21.26 | 2024 | |
| Tempus Ai, INC | $17.75 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $17.11 | 2025 | Yescarta |
| Stemline Therapeutics INC. | $16.08 | 2024 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wismer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.